IONIS PHARMACEUTICALS INC
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Oct 27, 2026 (1 day)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | BMO Capital | upgrade | Market Perform → Outperform | — | 53% |
| Oct 15, 2026 | UBS | upgrade | Neutral → Buy | — | 54% |
| Sep 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 22, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Sep 15, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 9, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 8, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Sep 8, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Sep 8, 2026 | BMO Capital | maintain | Market Perform → Market Perform | — | 53% |
| Sep 8, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Sep 8, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 4, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Sep 4, 2026 | BMO Capital | maintain | Market Perform → Market Perform | — | 53% |
| Sep 4, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 31, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 19, 2026 | BMO Capital | initiate | Outperform → Market Perform | — | 53% |
| Aug 3, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Jul 30, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 30, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 21, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 16, 2026 | Wolfe Research | downgrade | Outperform → Peer Perform | — | 53% |
| Jul 13, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 10, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jul 10, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 10, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jul 10, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 9, 2026 | Jefferies | maintain | Buy → Buy | — | 52% |
| Jul 9, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 25, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Jun 25, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 17, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 15, 2026 | TD Cowen | reiterate | Buy → Buy | — | 54% |
| Jun 1, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 19, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| Apr 30, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Apr 30, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 30, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 23, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Apr 21, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Apr 21, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Apr 9, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Mar 26, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Mar 25, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Mar 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 3, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Feb 27, 2026 | Piper Sandler | maintain | Overweight → Overweight | $100 | 54% |
| Feb 26, 2026 | Stifel | maintain | Hold → Hold | $77 | 53% |
| Feb 26, 2026 | Needham | maintain | Buy → Buy | $103 | 50% |
No cross-platform signals in the last 90 days